Verrica Pharmaceuticals (Nasdaq: $VRCA) Stock Hub 2026: Enrollment Closed In COVE-2, $11.2 Million Of Cash And A Going-Concern Statement

01 What Verrica Is In August 2026

Verrica Pharmaceuticals is a dermatology company with one approved product, one late-stage label
extension and one oncology asset that has finished Phase 2 and has not yet started Phase 3. It was
incorporated in Delaware on July 3, 2013, it is based in West Chester, Pennsylvania, and at
December 31, 2025 it had 76 full-time employees, all of them in the United States.

The approved product is YCANTH (VP-102), a drug-device combination containing a GMP-controlled
formulation of cantharidin, delivered through a single-use applicator. The U.S. Food and Drug
Administration approved it on July 21, 2023 for molluscum contagiosum in adult and paediatric
patients two years of age and older. It remains the first and only healthcare-professional-administered
product the agency has approved for that disease, which the company estimates affects around six
million people in the United States, mostly children.

Three things define the position as of August 27, 2026, and they pull in opposite directions.
Demand for the approved product is at its highest since launch: 19,626 dispensed applicator units in
the second quarter of 2026, up 28.3 per cent on the previous quarter and 46.1 per cent on the same
quarter of 2025. The label-extension programme reached a real milestone on the morning of
August 27, 2026, when the company announced that enrollment in COVE-2, the first pivotal Phase 3
trial in common warts, is complete, with topline data expected in the first quarter of 2027. And the
balance sheet is the tightest it has been: cash of $11.2 million at June 30, 2026, an operating cash
outflow of $18.4 million in the first half, and a statement in the quarterly report that substantial
doubt exists about the company’s ability to continue as a going concern.

The bridge between those facts is a credit agreement signed on August 3, 2026 for up to
$27.5 million, of which $12.5 million became available at closing. The lender is an entity controlled
by Paul B. Manning, chairman of the board and the company’s largest shareholder. Management stated
that the full amount, if drawn, could extend the cash runway into 2028.

02 YCANTH: Cantharidin, The Applicator And Why It Is Administered In The Office

Cantharidin is an old molecule with a modern regulatory problem. Dermatologists have used
compounded cantharidin on molluscum lesions for decades, but the compounded product was never
approved, never standardised and never subject to manufacturing control. YCANTH is the version that
went through the agency: a fixed 0.7 per cent formulation in a single-use applicator that allows
precise topical dosing on the lesion, applied in the office by a clinician rather than by the patient
at home.

That design decision explains most of the commercial story. Because the product is administered by
a healthcare professional, the unit that matters is not a prescription filled at a pharmacy counter
but an applicator dispensed to a treating physician. It also means the reimbursement conversation is
a buy-and-bill conversation with payors and practices rather than a retail pharmacy one, and that the
sales force is calling on dermatology and paediatric offices, not on a mass market.

The registrational package was CAMP-1 and CAMP-2, registered as NCT03377790 and NCT03377803, two
Phase 3 vehicle-controlled trials of 266 and 262 subjects that both completed in 2018, with a primary
endpoint of complete clearance of all treatable molluscum lesions at Day 84. That evidence base is what the 2023 approval rests on, and it
is also what Torii used in Japan, where approval came on the basis of an additional Phase 3 trial of
approximately 300 patients.

The same applicator and the same molecule are what the company is now trying to move into a second,
much larger indication. Nothing about the delivery system changes for common warts; what changes is
the dosing interval, the number of applications and the patient population.

03 The Commercial Ramp: Units Against Dollars

Dispensed applicator units have risen in every quarter the company has reported since the end of
2024, and the commercial line is also the part of the business that has generated the most
disagreement among the people who follow the stock, because unit growth and revenue growth have not
moved at the same speed.

Cumulative dispensed units passed 100,000 since launch during the first quarter of 2026. The second
quarter of 2026 was the highest quarterly total the product has recorded.

The reason units grow faster than dollars is gross-to-net: the difference between the list price of
an applicator and what the company actually collects after rebates, discounts, chargebacks, patient
assistance and returns. Verrica reports net product revenue, so any widening of that gap shows up as
units rising faster than revenue. In the second quarter of 2026 units were up 46.1 per cent year on
year while U.S. net product revenue was up 12.3 per cent, and the company attributed the revenue
increase primarily to increased deliveries to distribution partners. The company has not published a
gross-to-net percentage, so the size of the gap is not directly verifiable from the filings.

The cost of producing that growth is visible in the other direction. Selling, general and
administrative expense was $10.3 million in the second quarter of 2026 against $8.9 million a year
earlier, and the company attributed the $1.3 million increase, excluding stock-based compensation,
primarily to increased commercial spend related to the expansion of the sales force. Put the two
lines side by side and the position is plain: the commercial organisation costs about twice what the
product it sells brings in.

04 Japan, Israel And Europe: The Partnered Perimeter

Outside the United States, Verrica does not sell the product itself. It licenses it, and the
partner perimeter now covers three territories with three different structures.

Japan, and the partner that also funds the pipeline

The Japanese agreement was signed with Torii Pharmaceutical on March 17, 2021. Torii is a
wholly-owned subsidiary of Shionogi. It has an exclusive licence to develop and commercialise
cantharidin-containing products for molluscum and common warts in Japan, and a right of first
negotiation on additional indications there.

The Japanese approval of TO-208, the local name for YCANTH, came in September 2025, and Torii paid
Verrica a $10.0 million milestone in cash at that point rather than offsetting it against programme
costs as the earlier amendment had contemplated. A separate $8.0 million milestone, accelerated by
the second amendment, was paid in July 2025 and recognised in the second quarter of that year. Those
two payments are the reason the 2025 revenue line looks the way it does, and neither of them repeats.

The agreement also sets up a manufacturing transfer to Torii, expected to take several years, after
which Verrica begins earning royalties on Japanese net sales of applicators made by Torii instead of a
transfer price on completed applicators it ships itself.

Israel

On July 21, 2026 Verrica signed an exclusive distribution, marketing and supply agreement with
Medomie Pharma for YCANTH in molluscum contagiosum in Israel. Verrica manufactures and supplies the
product and receives a share of product sales plus certain regulatory and commercial milestone
payments. No financial terms were disclosed.

Europe, where the file is open and the date is not

On October 20, 2025 the company announced that the Committee for Medicinal Products for Human Use
of the European Medicines Agency had given positive feedback supporting the filing of a Marketing
Authorisation Application for YCANTH in molluscum contagiosum in the European Union, with no
requirement to complete additional clinical studies. During the first quarter of 2026 Verrica formed a
wholly-owned Irish subsidiary to facilitate regulatory filings in the European Union, and that
subsidiary had no material operations in the six months to June 30, 2026.

What has not been announced is a submission date, an assigned rapporteur or an opinion timeline.
A regulatory pathway that removes the need for new clinical work is a real reduction in cost and
risk, but until a filing is confirmed there is no European clock running.

05 Common Warts: The COVE Programme And The August 27 Enrollment Milestone

Common warts is the reason the equity has a story larger than a $15 million product. Verrica
estimates prevalence at approximately 22 million patients in the United States alone, against roughly
six million for molluscum, and there is no FDA-approved prescription drug therapy for the indication.
Patients use over-the-counter treatments with limited success and frequent recurrence. Around half of
the patients who seek treatment in the United States are children, which is the same call point the
existing sales force already covers.

What was announced on August 27, 2026

Before the market opened on August 27, 2026 the company announced that enrollment in COVE-2, the
first pivotal trial of the global Phase 3 programme, is complete. Three specifics matter in that
release. A per-protocol interim statistical power analysis, run by an independent statistician,
confirmed that no additional subjects are recommended for full enrollment. The study remains fully
blinded to the company and to the study team, so the interim analysis says something about the
adequacy of the sample, not about the direction of the result. And COVE-3, the second pivotal trial,
has already passed 50 per cent of its current target enrollment, which the company described as ahead
of schedule.

The timing guidance moved with it. Topline data from COVE-2 are now expected in the first quarter of
2027. On August 6, 2026, three weeks earlier, the company had guided to topline data from the
programme in mid-2027. The August 27 release keeps mid-2027 for the remaining data and pulls the first
readout forward into the first quarter.

The design

The programme is two double-blind, randomised, vehicle-controlled studies, COVE-2 and COVE-3, of
VP-102 in the United States and TO-208 in Japan, applied once every 21 days for up to four
applications, in patients aged two and above. COVE-2 enrolled in the United States only. COVE-3
enrolls in the United States and Japan; the company announced on June 22, 2026 that its first United
States patient had been dosed, and first patients in both countries were dosed during the second quarter. A long-term follow-up study, COVE-4, and a
pharmacokinetics study, COVE-5, sit alongside them.

The registry entries lag the company releases: at the time of reading, on August 27, 2026, COVE-2
was still listed as recruiting and COVE-3 as not yet recruiting, against a company statement that the
first patients in COVE-3 were dosed in June 2026. Where the two disagree, the dated company release is
the more recent record.

Who pays for it

Verrica and Torii split the cost of the global Phase 3 programme 50/50, and Torii pays the first
$40.0 million of out-of-pocket costs when due, which the company describes as approximately 90 per
cent of the current trial budget. Verrica repays its half over time, not in cash but by offsetting
amounts otherwise due from Torii: future royalties, certain transfer-price payments and remaining
development milestones. Above $40.0 million, Verrica pays the excess up to a specified maximum and
Torii repays half of that over time.

This is the single most important structural fact about the programme’s effect on the balance sheet.
Research and development expense rose to $6.0 million in the second quarter of 2026 from $1.8 million
a year earlier, almost entirely because of common warts, and the company states that the expense did
not affect its cash balance. The accounting cost and the cash cost of this trial are not the same
number, and the repayment is deferred into a revenue stream that only exists if the Japanese business
grows.

06 What COVE-1 Actually Showed, And What It Cannot Show

The Phase 3 programme rests on COVE-1, an open-label Phase 2 trial in subjects with up to six
common warts, registered as NCT03487549, with 56 subjects, which read out in 2019. Complete clearance
of warts at Day 84 was observed in 19.0 per cent of subjects in Cohort 1 and 51.4 per cent in
Cohort 2.

The spread between those two numbers is the reason the Phase 3 is a genuine test rather than a
formality, because the two cohorts were not the same experiment. Cohort 1 ran at a single site with
21 subjects aged two and older, treated up to four times with at least 14 days between treatments.
Cohort 2 ran at four sites with 35 subjects aged twelve and older, treated up to four times every
21 days, and paring of the wart before application was allowed. Mean decrease from baseline in the
number of warts at Day 84 was 31.2 per cent in Cohort 1 and 53.8 per cent in Cohort 2. Age, number of
sites, dosing interval and paring all differ, so the gap between 19.0 and 51.4 per cent cannot be
assigned to any one of them. An open-label trial of 56
subjects with no vehicle arm cannot tell how much of that clearance would have happened anyway:
common warts resolve spontaneously in a meaningful share of patients, particularly children, and the
vehicle arm in COVE-2 and COVE-3 exists precisely to measure that. A vehicle-controlled Phase 3 has to
beat spontaneous resolution plus placebo effect, not zero.

The endpoint is the same construct that worked in molluscum: proportion of subjects with complete
clearance of all treatable common warts, baseline and new, at the end-of-treatment visit on Day 84.
Complete clearance of every treatable lesion is a demanding bar, and it is the bar the molluscum
programme cleared twice.

07 VP-315 In Basal Cell Carcinoma: Phase 2 And The Abscopal Signal

VP-315, now named ruxotemitide and formerly LTX-315, is an oncolytic peptide injected directly into
a tumour to induce immunogenic cell death, releasing tumour antigens and provoking a T-cell response.
Verrica licensed it from Lytix Biopharma in August 2020, on an exclusive worldwide basis, for
malignant and pre-malignant dermatological indications other than metastatic melanoma and metastatic
Merkel cell carcinoma. The initial focus is basal cell carcinoma and squamous cell carcinoma. Basal
cell carcinoma is the most common cancer in the United States, with approximately 3.6 million
diagnoses a year, and the standard of care is surgical excision.

What the Phase 2 showed

The Phase 2, registered as NCT05188729, enrolled 92 subjects and completed in April 2024. In Part 2,
approximately 51 per cent of treated tumours achieved complete histologic clearance. Every treated
tumour showed a reduction in size. Overall tumour size reduction was 86 per cent, and in subjects who
still had residual tumour the reduction was 71 per cent. In November 2024 the company reported a
post-hoc calculated objective response rate of 97 per cent, defining response as no disease
progression together with at least a 30 per cent tumour reduction and a partial or complete response.

The abscopal signal, and how large the dataset actually is

The data presented at the Society for Investigative Dermatology annual meeting on May 15, 2026,
poster LB1190, announced by the company on May 5, 2026, concern lesions that were never injected. Subjects received intratumoral VP-315
injections of less than 8 mg in 0.5 mL in up to two treated lesions, and up to three non-treated
lesions per subject were monitored over 12 weeks.

Reductions were seen in non-treated lesions proximal, distal and contralateral to the treated ones,
which is the observation that supports the abscopal reading rather than a local diffusion one. The
company’s own framing is careful: it says the activity suggests a potential abscopal effect
consistent with broader immune activation. Fourteen lesions in nine subjects, in an open-label study,
is a signal to be tested, not a demonstrated effect, and the release says so.

08 The End-Of-Phase-2 Feedback, And Why The Phase 3 Has Not Started

In March 2025 the company obtained end-of-Phase-2 feedback from the FDA that supports what it
describes as an efficient Phase 3 programme and path to registration for VP-315. The shape agreed is
two placebo-controlled Phase 3 studies of approximately 100 subjects each, with a primary endpoint of
complete clearance at week 14. Additional long-term follow-up studies are deferred to post-approval
commitments, which removes years from the critical path.

Two hundred subjects across two trials with a 14-week primary endpoint is, by the standards of
oncology development, a small and fast programme. That is the asymmetry in the asset: a
non-surgical option in a cancer that is currently cut out, tested in a package that a company of this
size could in principle run.

It has not started. The company states that it has initiated clinical and chemistry, manufacturing
and controls activities to prepare the commencement of Phase 3, describes VP-315 as Phase 3-ready and
says it is continuing Phase 3 readiness activities. It also says it may pursue non-dilutive strategic
partnerships to help fund the development and commercialisation of the asset. No start date has been
given, and the segment note puts $68 thousand of research spending against VP-315 in the three months to
June 30, 2026 and $201 thousand in the half, against $3.4 million for common warts in the quarter alone.

The spending pattern is the clearest statement of priority the filings contain. With cash of
$11.2 million at June 30, 2026, the common warts programme is being run largely on Torii’s money and
VP-315 is being held at readiness rather than advanced. On the company’s own description, a partner or a financing is
what turns VP-315 into an active programme, and neither has been announced.

09 Second Quarter 2026 In Numbers

The second quarter of 2026 was reported on August 6, 2026, together with the quarterly report on
Form 10-Q and the credit agreement announced the same afternoon.

The year-on-year comparison flatters the prior period and punishes this one, for a reason that is
disclosed rather than hidden: license and collaboration revenue of $8.2 million in the second quarter
of 2025 included an $8.0 million one-time milestone payment from Torii. Strip it out and the
underlying comparison is product revenue of $5.1 million against $4.5 million, plus roughly $0.2
million of supply and development activity against $0.8 million this year.

Three cost movements move independently of each other. Research and development rose $4.2 million, of
which the company attributes $4.1 million excluding stock-based compensation to the common warts
Phase 3, the programme Torii funds. Interest expense fell $2.0 million because the OrbiMed debt
facility was settled and terminated in November 2025. And $1.7 million was recognised as the company
reached an agreement in principle to settle the class action brought against it in 2022 over
disclosure of manufacturing inspection issues; the figure is Verrica’s share after insurance recovery.

The reported loss and the cash cost of running the business are not the same figure this quarter.
The $13.2 million net loss includes $1.7 million of settlement, non-cash stock-based compensation, and
the accounting charge for a trial being paid for by someone else. The operating cash outflow for the
whole first half was $18.4 million.

10 Cash, Burn And The Going-Concern Statement

Cash was $11.2 million at June 30, 2026, against $20.6 million at March 31, 2026 and $30.1 million
at December 31, 2025. The accumulated deficit stands at $347.7 million and total stockholders’ equity
had fallen to $4.3 million from $24.7 million at the start of the year.

The quarterly report states the position directly, and the wording is the wording that matters most
in the whole filing: “Based on our current business plan and current capital resources, including
$12.5 million available under the PD Credit Agreement, combined with the uncertainty regarding the
availability of additional funding, we have concluded that there is substantial doubt regarding our
ability to continue as a going concern within one year after the date these consolidated financial
statements are issued.”

That sentence includes the new facility. The going-concern conclusion is not a description of the
position before August 3, 2026; it is the position with the first $12.5 million tranche counted.

The arithmetic behind it is straightforward. Operating cash outflow was $18.4 million over six
months, about $3.07 million a month. Cash alone, at $11.2 million, is around three and a half months
at that rate from June 30. Cash plus the $12.5 million available tranche is $23.7 million, which is
about seven and a half months from June 30 and therefore around five and a half months from
August 27, before any interest paid in cash rather than in kind and before the second tranche. The company
plans to address the doubt by borrowing the additional amounts under the facility and obtaining
further funding through equity offerings, debt financing, collaborations, strategic alliances or
licensing arrangements.

Management’s own runway statement is conditional and stated as such: based on the current operating
plan, the full $27.5 million that may be available under the facility could extend
the cash runway into 2028. Both the availability of the second tranche and the runway that follows
from it depend on conditions the company has not published.

11 The Manning Credit Facility: Terms, Cost And Who Is On The Other Side

The credit agreement was entered into on August 3, 2026 with PD Joint Holdings, LLC Series 2016-B,
an entity controlled by Paul B. Manning, the chairman of Verrica’s board and its largest shareholder.
It is the reason the going-concern statement is survivable rather than terminal, and it is also a
related-party transaction that puts the company’s assets behind a loan from its own chairman.

Three features of that table compound each other. The rate has a hard floor of 12.50 per cent a year,
which for a company with $11.2 million of cash and $10.9 million of half-year revenue is expensive
money. The PIK option means the interest does not have to be paid in cash while the company is
solvent, which preserves runway but grows the principal. And the security covers substantially all
assets, which includes the YCANTH franchise and the licensed rights that sit behind the pipeline.

The company presented it as non-dilutive growth capital, and in the narrow sense that is accurate:
no shares were issued. The dilution risk it removes today is real. What it introduces instead is a
secured claim ahead of shareholders, priced above 12 per cent, maturing at the end of 2030, held by
the chairman.

12 Capital Structure, Warrants And The One-For-Ten Reverse Split

The capital structure has been rebuilt twice in eighteen months, and both events still shape what
the share price means.

The reverse split

On January 24, 2025 Verrica received written notice from Nasdaq that it was not in compliance with
the minimum bid price requirement for continued listing. The company effected a one-for-ten reverse
stock split, effective at 5:00 p.m. Eastern Time on July 24, 2025 under the certificate of amendment
filed that day, with the shares trading on a split-adjusted basis from July 25, 2025, and stated that
it regained compliance. Every per-share
figure before that date, in any chart or screen that has not been adjusted, is off by a factor of ten.

The November 2025 private placement

On November 23, 2025 the company signed securities purchase agreements to sell 6,499,826 shares of
common stock, pre-funded warrants over 5,305,164 shares to certain purchasers in lieu of shares, and
accompanying Series C warrants over 2,951,241 shares. The price was $4.24125 per share and accompanying
warrant, and $4.24115 for the pre-funded warrant version. That transaction is what retired the OrbiMed
debt and reset the balance sheet. At December 31, 2024 the loan facility stood at $31.0 million of
long-term debt plus $12.9 million classified as current, a total of $43.9 million; on November 26,
2025 the company extinguished it by paying a cash settlement of $35.0 million, and debt was zero at
December 31, 2025.

Where the count stands

At June 30, 2026 there were 17,189,300 shares issued and 10,514 held in treasury, leaving 17,178,786
outstanding, the same figure the company reported on the cover of the quarterly report as of
July 31, 2026 and unchanged since December 31, 2025.

Two conclusions follow from that table, and they are opposite in sign. The pre-funded warrants have
an exercise price of $0.0001 and no expiry, and the company includes them in basic loss per share
because exercise is virtually assured, so the real working share base is 21,305,025, not 17,178,786.
At the August 26, 2026 close of $4.91 that is a market value of about $104.6 million on the
as-converted count, against the $84.4 million a screen computes on the outstanding count alone.

On the other side, everything else is struck well above the current price. Total potentially
dilutive securities excluding the pre-funded warrants were 8,335,926 at June 30, 2026 against
5,968,904 a year earlier, but the Series C at $6.3150, the Series B at $13.35, the OrbiMed warrants at
$23.5541 and the Torii warrants at $95.60 are all out of the money at $4.91. The Series A warrants from
the 2024 offering expired unexercised in November 2025. The near-term dilution overhang is therefore
smaller than the headline count suggests, and the funding it would have provided is correspondingly
absent.

Two grants of options sit outside that table, and they are different instruments. The first was
approved by a board committee on December 23, 2025 subject to shareholder approval of an amendment to
the 2018 Equity Incentive Plan, which shareholders gave on June 5, 2026: options struck at $8.21 and
expiring on December 23, 2035, over 512,269 shares to the chief executive, 233,840 to the chief
medical officer and 171,340 to the chief operating officer. The whole of that grant is conditioned on
the share price: half vests when the closing price reaches at least $15.00 and the other half when it
reaches at least $25.00. At $4.91, the first hurdle is three times away and the second five times.
The second grant is the annual director award made on June 5, 2026: 16,000 options each, struck at
$6.04, expiring on June 4, 2036 and vesting in twelve equal monthly instalments, with no price
hurdle.

13 Ownership: A Chairman Capped At 49.99 Per Cent

Ownership is the most unusual feature of this company, and it explains both the financing that keeps
it alive and the limited free float that moves the price.

The figures are from the beneficial ownership table in the proxy statement filed on April 20, 2026
and are stated as of April 8, 2026. The Manning holding includes 1,310,652 shares issuable on exercise
of warrants, which the proxy explains is the maximum issuable within the applicable window given a
beneficial ownership limitation set at 49.99 per cent.

That limitation is the structural fact. The chairman is capped just under half the company, holds
warrants he cannot fully exercise without breaching the cap, and is now also the secured lender. Two
institutions hold another 15 per cent between them. What is left as genuine free float is a small
fraction of a 17 million share count, which is consistent with the volume the stock actually trades:
an average of about 55,000 shares a day over the last thirty sessions to August 26, 2026.

The underlying disclosure is a Schedule 13D/A filed on November 28, 2025 for the event date of
November 25, 2025 by Mr Manning together with PBM Capital Investments and BKB Growth Investments, which
reports the same 49.9 per cent position and the 49.99 per cent beneficial ownership limitation. A
further Schedule 13D/A was filed on December 30, 2025 by the Caligan group.

14 Management, And The Insider Buying Of Mid-August

Jayson Rieger, PhD, MBA, is president and chief executive officer and has served since 2024.
John J. Kirby has been interim chief financial officer since November 2024, a temporary title that has
now run for twenty-one months. Noah Rosenberg, MD, has been chief medical officer since March 2025.
David Zawitz serves as chief operating officer, chief legal officer and secretary. Paul B. Manning has
been chairman since 2017. Chris Chapman appears on the company’s leadership page as chief commercial
officer and is not among the executive officers listed in the April 2026 proxy statement.

What the officers did in the middle of August

Four officers filed Form 4s on August 18, 2026 reporting open-market purchases made between
August 14 and August 18, at prices between $4.91 and $5.06.

Four officers buying in the same week, twelve days after a going-concern statement, is not costless
to them and it is the clearest read available on what management thinks of the price. It is also
about $211,000 in total, against a business that consumed roughly $3.07 million a month in the first
half. Retail sentiment on Stocktwits rose sharply in the session after those filings appeared. The
purchases change the ownership register at the margin; they do not change the funding position.

15 Market Snapshot And Analyst Coverage

The whole 52-week range was set inside four weeks in November 2025: the intraday low of $3.28 on
November 4 and the intraday high of $9.821 on November 28, on either side of the private placement
signed on November 23 at $4.24125 per share. The high came on volume of 2.6 million shares, roughly
forty times the average session. Everything since has traded in the lower half of that range.

Analyst coverage

Verrica names six covering analysts on its own investor relations pages: Stacy Ku, Dev Prasad,
Raghuram Selvaraju, Serge Belanger, Dennis Ding and Kemp Dolliver. The company publishes the names
only. It does not publish the firms, the ratings or the price targets, and it states that any opinion
or forecast made by those analysts is theirs alone. No rating or target is reported here, because none
could be attributed to a dated note from a named firm. Six analysts on a company of this size is a
thin consensus in any case, and it carries less information than the enrollment announcement of
August 27 or the going-concern paragraph of August 6.

16 Retail Sentiment On Stocktwits

Stocktwits is a retail message board, and the readings below are what non-professional traders were
saying on August 27, 2026. They carry no analytical weight beyond that.

The month has a clear shape. Sentiment sat between 46 and 55 for three weeks, including through the
second-quarter release on August 6 and the going-concern statement inside it, then jumped to 77 on
August 19, the session after the four Form 4s were filed, held in the seventies for three days and
dropped to 38 on August 26. Message volume tells the same story from a different angle: the current
bucket reads 39 out of 100 and is labelled low, while the one-month bucket reads 72 and is labelled
high, which is what a spike inside an otherwise quiet stream looks like.

The bear case on the stream is stated as plainly as the bull case: posts pointing to weak physician
adoption relative to spending, to cash having run down, and to expensive new debt being added. The
monetisation argument, that units surged while revenue barely moved, is the sharpest of them, and it
is the same gap that shows in the reported numbers.

17 The Catalyst Map

Each date is stated as the company stated it, with confirmed dates separated from windows.
None of them is a forecast of an outcome.

The structure of that map is what constrains the company. The two events that would change the
equity most are both in 2027, and everything between now and then is financing, commercial execution
and the possibility of a partnership. Counting cash at June 30 plus the available tranche, funded
operations run about seven and a half months from that date, which is around five and a half months
from August 27, against a first pivotal readout roughly two quarters away.

18 Risks And Red Flags

Going concern

The quarterly report filed on August 6, 2026 concludes that substantial doubt exists about the
ability to continue as a going concern within one year of issuance, and that conclusion already counts
the $12.5 million available under the credit facility. This is a stated conclusion of the company’s
own management, not an inference.

The lender is the chairman

The facility is secured on all or substantially all assets and is held by an entity controlled by
the chairman and largest shareholder. It aligns his interests with survival, which is a genuine
positive. It also means that in a restructuring the secured claim ahead of the common stock belongs to
the person who controls close to half of the common stock, and that a related-party negotiation would
be a negotiation about both sides of the table.

Cost of capital

Interest is the greater of SOFR floored at 4.50 per cent plus 8.00 per cent, and 12.50 per cent a
year, against half-year revenue of $10.9 million. Payment in kind preserves cash and grows principal
toward a December 31, 2030 maturity.

Monetisation

Dispensed units rose 46.1 per cent year on year in the second quarter while U.S. net product revenue
rose 12.3 per cent. The company has not disclosed a gross-to-net figure, so the size of the gap cannot
be verified from the filings.

Binary dependence on a single 2027 readout

COVE-2 is vehicle-controlled, and the Phase 2 that supports it was open-label with 56 subjects and a
19.0 per cent to 51.4 per cent spread between cohorts. Common warts resolve spontaneously in a
meaningful share of patients. A failure would remove the reason for most of the current spending.

Dependence on one partner

Torii funds approximately 90 per cent of the current warts trial budget and generates the Japanese
royalty stream out of which Verrica repays its half. Concentration also appears on the balance sheet:
the quarterly report discloses customer concentration in accounts receivable.

Litigation

An agreement in principle was reached to settle the 2022 securities class action, at a cost to
Verrica of $1.7 million after insurance recovery. Agreements in principle are not final settlements
until documented and approved.

Listing history

A minimum bid price notice in January 2025 was cured by a one-for-ten reverse split in July 2025.
The company states it regained compliance and the current filings disclose no open deficiency. At
$4.91 the bid price requirement is not currently in question.

Interim finance leadership

The chief financial officer has held the role on an interim basis since November 2024, through a
reverse split, a $50 million private placement, a debt retirement, a going-concern conclusion and a
related-party credit facility.

19 Merlintrader Health Score

The Merlintrader Health Score is a 1 to 5 reading of balance-sheet robustness and execution over a
12 to 18 month horizon, weighted balance sheet and runway 30 per cent, catalysts 30 per cent, dilution
20 per cent, liquidity 10 per cent and execution 10 per cent. It is not a buy or sell indication and
carries no view on the share price.

Weighted result: 2.3 out of 5. The first pillar dominates the reading, which would
move materially on either a completed financing or a delay to the first quarter 2027 readout.

20 Scenarios

Both arguments are set out as the people who hold them make them, mapped to the events that would
decide between them. They carry no probabilities and no price levels.

The case those who are constructive make

Their argument is that the hard part is already funded by somebody else. Torii pays roughly 90 per
cent of the warts trial budget, enrollment in the first pivotal trial closed ahead of plan with an
independent statistician confirming the sample is adequate, and the second is running early. The
addressable population in common warts is around 22 million in the United States with no approved
prescription therapy, and the same sales force that is already growing molluscum units 46 per cent a
year would carry the second indication. VP-315 sits behind it with a 51 per cent complete histologic
clearance rate in Phase 2 and an agreed two-trial, 200-subject Phase 3 design. On this reading, the
chairman lending against the assets at 12.5 per cent, and four officers buying shares in the same
week, are the people with the most information choosing to fund and hold.

The case those who are negative make

Their argument is that the company runs out of time before any of that matters. Cash of
$11.2 million plus the $12.5 million tranche is a little over seven months at the current burn, the
first readout is in the first quarter of 2027, and the stated plan to close the gap includes equity
offerings from a company whose shares are at $4.91 after a one-for-ten reverse split. Three years
after approval the product generates $5.1 million a quarter against $10.3 million of quarterly
selling and administrative cost, and units are growing four times faster than revenue. The European
filing has no date, VP-315 has no start date and $68 thousand of quarterly spending, and the new money
is secured debt at above 12 per cent from a related party rather than an arm’s length lender or a
commercial partner.

What would settle it

Four things, in order of when they can be observed: whether a financing is completed and on what
terms; whether the third-quarter numbers narrow the gap between unit growth and revenue growth;
whether the second $15.0 million tranche becomes available; and, in the first quarter of 2027, whether
COVE-2 meets its primary endpoint against vehicle.

21 Bottom Line

Verrica in late August 2026 is a company whose clinical execution is running ahead of its balance
sheet. The two documents that define it were filed three weeks apart and point in opposite
directions: a quarterly report on August 6 that concludes substantial doubt about the going concern
even after counting the new credit line, and a release on August 27 that closes enrollment in the
first pivotal trial early, with an independent interim analysis confirming the sample is sufficient
and topline data pulled forward into the first quarter of 2027.

Between those two facts sits a commercial product at record demand that still does not pay for its
own sales force, a Japanese partner carrying about 90 per cent of the pivotal trial budget, an
oncology asset that is Phase 3-ready and took $68 thousand of research spending in the second quarter,
and a chairman who holds
close to half the shares and is now also the secured lender at a rate floored at 12.5 per cent.

What happens next is not, in the first instance, a question about the science. It is a question
about whether around five and a half months of funded operations, measured from August 27 and counting
the available tranche, can be extended far enough to reach a readout roughly two quarters away, and on
what terms. Each figure carries its own reference date, and the ones that matter most have a short
shelf life.

Related Research On Merlintrader

• Verrica Pharmaceuticals (VRCA): deep dive 2026 after the balance-sheet reset
• Verrica Pharmaceuticals: VP-315 Phase 2 data put a fresh spotlight on basal cell carcinoma
• VRCA, Verrica Pharmaceuticals Inc: the November 2025 situation
• Top ten biotech stocks right now